Adding insulin detemir to a treatment regimen of metformin and liraglutide improved glycemic control and led to sustained weight loss for up to 52 weeks in patients with type 2 diabetes.…

A measure of the postprandial ratio of urinary C-peptide to creatinine (UCPCR) can distinguish maturity-onset diabetes of the young (MODY) from type 1 diabetes mellitus, allowing some children who would otherwise be treated with insulin to receive oral antidiabetic agents alone….

While searching for potential cardiovascular risks among studies involving dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes patients, researchers made a surprising discovery –- treatment with the so-called gliptin class appears to protect the heart.…

New data on two investigational glucagon receptor antagonists suggest that this novel class of drugs has potential to be an effective treatment for type 2 diabetes.…

  In patients diagnosed with type 2 diabetes, elevations in blood levels of glucose and glycated hemoglobin (HbA1c) can be seen as much as 10 years prior to diagnosis.…

The investigational drug ipragliflozin improved glycemic control and decreased body weight and blood pressure, according to the phase III BRIGHTEN study.…

Two biomarkers may be associated with cardiovascular events and death in type 2 diabetes patients, researchers reported at EASD.…

Aggressively lowering blood pressure and blood glucose together won’t provide any microvascular benefits to type 2 diabetes patients, researchers said….

Dementia risk may rise when glucose gets out of control, particularly after meals, according to a longitudinal study.…

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin….